The role of steroid in rheumatic diseases


Published on

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

The role of steroid in rheumatic diseases

  1. 1. Rachmat Gunadi WachjudiLahir di Garut, 16-1-1955Pendidikan SD-SMA : Garut Dokter umum: FK UNSRI Palembang Internist: FK UNPAD Bandung Konsultan Reumatologi : FK UI Jakarta Clinical Rheumatology & Osteoporosis training Arthritis foundation of WAPekerjaan: Staf Reumatologi RS Dr Hasan SadikinOrganisasi Profesi IDI, IRA, PAPDI, PEROSI, PERALMUNI, IPS, ISS
  2. 2. The Role of Corticosteroid inRheumatic Diseases Rationale & Therapeutic principles
  3. 3. INTRODUCTION Corticosteroid use is one of the most important and controversial subjects in rheumatology. The dramatic anti-inflammatory effects of corticosteroids were first described in the setting of treating rheumatoid arthritis (RA). This unexpected discovery by Philip Hench resulted in Nobel price in 1950. Long-term supraphysiologic therapy produced devastating side effects led to polarized views of the role of corticosteroids in the pathogenesis & therapy of rheumatic diseases.Hench PS etal. Proc Staff Meet Mayo Clin 24:181, 1949Hench PS etal. Arch Intern Med 85:545,1950
  4. 4. Steroids the Sleaziest of Drugs Steroids are fast catching up with antibiotics as the most abused class of drugs in doctors black bag. High doses of corticosteroids and other immunosuppressive agents cause AIDS Mohammed Ali Al-Bayati Ph.D
  5. 5. Corticosteroid Physiology Essential for normal development & maintenances of homeostasis during both basal and stress conditions. Represent one of the most important products of the hypothalamic – pituitary – adrenal (HPA) axis & the central response system. Regulate a broad array of metabolic and central nervous system (CNS) functions Potent anti-inflammatory actions.
  6. 6. Cortisol Secretion
  7. 7. Anti-inflammatory actions of corticosteroids Corticosteroid inhibitory effect
  8. 8. Role in Rheumatic diseasesMost of the desired clinical effects of GC treatment in rheumatic patients are mediated by transrepression.These include:1. Reduction of clinical signs & symptoms of inflammation by reducing synthesis of enzymes involved in the biosynthesis of prostaglandin E2 and pro inflammatory cytokines, such as IL1 & TNF – alpha.2. Retardation of the radiological progression in rheumatoid arthritis
  9. 9. Major Rheumatic Diseases Osteoarthritis  Poly- Rheumatoid Arthritis Dermatomyositis Systemic Lupus  Crystal - Induced erythematosus Arthritis  Septic Arthritis Systemic Sclerosis  Vasculitis Spondyloarthropathies
  10. 10. Joint Swelling inflammation
  11. 11. What happens in inflammation? Associated with the production of cytokines (TNF & IL1, IL6)  stimulate HPA axis and corticosteroid production  feedback suppression of cytokine production & the inflammatory response. Inadequate corticosteroid production amplify inflammatory mechanisms & concomitant tissue injury. Defects in this bidirectional feedback loop between CNS & peripheral inflammatory pathways and/or tissue resistance to the actions of corticosteroids are suspected to contribute to several rheumatic disorders including RA. Wilder RL. Annu Rev Immunol, 13:307,1995 Chrousos GP. N Engl J Med 332:1351,1995
  12. 12. Glucocorticoid Use in Daily Practice. GC dosages in different clinical conditions is essentially empirical. High activity & severity need higher doses. The rationale is:a/ Higher doses increase cGCR saturation in a dose dependant manner which intensifies the therapeutically relevant, genomic actions.b/ Non genomic action of GCs increasingly come into play with increasing dosage
  13. 13. Standardized nomenclature for glucocorticoid dosesand glucocorticoid treatment regimens.Terminology Dosage Clinical Genomic actions Nongenomic actions application (receptor saturationLow dose <=7.5 Maintenance +(<50%) ? therapy for many rheumatic diseasesMedium dose >7.5 to <=30 Initially given in ++ (>50% to (+) primary chronic <100%) rheumatic diseasesHigh dose >30 to <= 100 Initially given in ++(+)(almost + subacute 100%) rheumatic diseasesVery high dose >100 Initially given in +++([almost] ++ acute and/or 100%) ++ potentially life- threatening exacerbations of rheumatic diseasesPulse therapy >=250 for one +++(100%) +++ or a few days
  14. 14. Short Acting Preparations (t1/2 < 12 h)Drug Anti-inflam. Salt retaining Preapartions & doseCortisol 1 1.0 5 mg tablet 100 mg/vial (i.m., i.v) Topical; enemaCortisone 0.8 0.8 5 mg tablet 25 mg/vial (i.m) Intermediate Acting Preparations (t1/2 = 12 -36 h)Prednisone 4 0.8 -Prednisolone 5 0.3 5, 10 mg tablet 20 mg/vial (i.m, intrarti)Methyl 5 0 0.5, 1.0 gm inj. for i.m.prednisolone or slow i.v.Triamcinolone 5 0 4 mg Tab., 10, 40 mg/ml for i.m. & intrarticular inj.
  15. 15. Therapeutic principles Dose selection empiric; Needs frequent evaluation Single dose: No harm Few days therapy unlikely to be harmful Incidence of side effects related to duration of therapy Use is only palliative (except replacement therapy) Inter-current illness: Dose is doubled Abrupt cessation of prolonged high dose leads to adrenal insufficiency (contraindicated)
  16. 16. Steroids in RA. Attractive options for many patients with new-onset inflammatory arthritis since they are rapid acting and may be used intra articularly or systemically & since the dose may be titrated to achieve meaningful control while evaluation continues.. Dramatically effective when used acutely but may be hazardous when used chronically. For these reasons, steroids should be avoided, weaned or used at the lowest possible dose after their introduction.. Adverse events are numerous. The long term use of these drugs, even at low doses, may be associated with significant reversible & irreversible toxicities.. The frequency of toxicity is proportional to the dose & duration of therapy.
  17. 17. Corticosteroids therapy is most effective and appropriate in three scenarios of early inflammatory arthritis.1/ New onset early (<12 weeks) undifferentiated inflammatory arthritis in which oral, IM or IA steroids can be given in very early patients with the hope of inducing remission.2/ New – onset RA for which prednisolone can be used as symptomatic therapy (usually in doses of 5-20 mg/day) in the first few weeks while the workup & symptoms evolve.3/ Early – aggressive RA for which prednisone can be used as adjuvant therapy (usually part of DMARD combination regimen) where in high – dose prednisone (60 mg/day) acutely is followed chronically by 5-10mg daily
  18. 18. Acute Gout
  19. 19. Intraarticular CorticosteroidsIndicated in:1/ Patients with new onset inflammatory monoarthritis2/ Acute focal flares of one or few joints3/ Patients disabled by synovitis in one joint despite effective systemic therapyShould be avoided in:1/ Neuropathic joints2/ Infected joint or overlying cellulitisMost effective initially and less effective with repeated injections.
  20. 20. Preparation Methyl Prednisolone Triamcinolone: 40 mg/mlor 10 mg / ml
  21. 21. Knee joint Patella Lateral Suprapatellar BursaAnteriolateralInferiopatellarApproach Patellar Tibial Tendon Plateau
  22. 22. Joint Swelling - Synovial EffusionArthrocentesis and Injection therapy
  23. 23. Subacromial bursa
  24. 24. De Quervain’stenosynovitis
  25. 25. Trigger finger
  26. 26. Plantar fasciitis
  27. 27. Pulse Corticosteroid Therapy. Indicated in severe Lupus. 3 daily IV infusions of 1000 mg methyl prednisolone. Reserved for life threatening complications as nephritis, vasculitis, severe cytopenias, pericardial tamponade.. Concomitant Cyclophosphamide
  28. 28. Lupus nephritis (WHO III)
  29. 29. Vasculitis
  30. 30. Adverse reactions (1/2) Metabolic toxicity:  Iatrogenic Cushing’s syndrome  Hyperglycaemia, glycosuria, diabetes  Myopathy (negative nitrogen balance)  Osteoporosis (vertebral compression fracture)  Retardation of growth (children)  Hypertension, oedema,CCF  Avascular necrosis of femur The frequency of steroid toxicity is proportional to the dose and duration of therapy
  31. 31. Avascular bone-necrosis
  32. 32. Adverse reactions (2/2)• HPA axis suppression• Behavioral toxicity: Euphoria, psychomotor reactions, suicidal tendency• Ocular toxicity: steroid induced glaucoma, posterior subcapsular cataract.• Others: – Superinfections – Delayed wound healing – Steroid arthropathy – Peptic ulcer – Live vaccines are dangerous
  33. 33. Contraindications Infections Hypertension with CCF Psychosis Peptic ulcer Diabetes mellitus Osteoporosis Glaucoma Pregnancy : (prednisolone preferred)
  34. 34. Precautions during therapyFollowing examinations of the patient to bedone before, during and after steroidtherapy  Body weight  X-ray of spine  Blood glucose  Examination of the eye  B.P.
  35. 35. Information >>> Judgement
  36. 36. New Glucocorticoid Receptor Ligands1/ Time-release tablets: Already availabe in USA. Taken by night to optimize suppression of proinflammatory cytokines.2/ Liposomes: small molecules 100nm in size, used as carrier system for GC. Reported in mice to accumulate selectively at site of inflammation. Metselaar JM etal. A&R 2003,48:20593/ Glycyr-rhetinic acid: Inhibits 11 beta hydroxysteroid dehydrogenase thus increases level & action of endogenous GC.4/ Nitrosteroids: Aromatic molecules which links a conventional GC drug with nitric oxide (NO). enhance anti-inflammatory effect & induces less osteoporosis than CG in animal models. Paul – Clark MJ. Prox Natl Acad Sci USA 2002, 99:16775/ Selective glucocorticoid receptor agonists (SERGAs):Transrepression >> Transactivation Schackett etal. Proc Natt Acad Sci USA, 2004, 101:227
  37. 37. Thanks for your patience
  38. 38. Have a nice weekend